Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

social media

- PMLiVE

UK trial of Novavax COVID-19 vaccine demonstrates 89.3% efficacy

Vaccine demonstrated 60% efficacy in South Africa study

Holistic Digital Health Engagement and Risk Quantification

Matt Park, Vice President & General Manager (North America) at Dacadoo, explores digital health engagement and health risk quantification in the COVID-19 era, including the roles of gamification, big data,...

Impetus Digital

Can Science Save Us?

Dr. Mark Poznansky, Founder/Blogger at Saved By Science explores the importance of improving health literacy among the general population, along with the scientific and technological innovations that he believes could help save...

Impetus Digital

- PMLiVE

PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19

Early study results published in peer-reviewed journal Science

- PMLiVE

Lilly partners with GSK and Vir on COVID-19 antibody study

Study will test Lilly's bamlanivimab with GSK/Vir’s VIR-7831

- PMLiVE

AZ and EU fail to solve COVID-19 vaccine delivery issues

AZ temporarily reduced Q1 deliveries to the EU last week

- PMLiVE

South Africa COVID-19 variant ‘unlikely’ to reduce efficacy of Pfizer/BioNTech jab

Lab study tested blood samples of vaccinated individuals against key virus mutations

- PMLiVE

Sanofi will provide manufacturing support for Pfizer/BioNTech’s COVID-19 vaccine

Sanofi is aiming to provide 100 million doses of the vaccine by the end of the year

- PMLiVE

Eli Lilly’s COVID-19 antibody combination reduces risk of hospitalisations and death

High-risk patients treated with the two drugs had a 70% reduction in hospitalisation and death

- PMLiVE

Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine

Boosters will be designed to protect against new variants

- PMLiVE

Novartis hit by ‘COVID-19-related lockdowns’ in Q4

Sales grew in the quarter but profits fell short of forecasts

regeneron headquarters

Regeneron’s antibody cocktail prevents COVID-19 in high-risk patients

Monoclonal antibodies prevented 100% of symptomatic infections

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links